Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met

Anaplastic lymphoma kinase (ALK) is a validated molecular target for patients harboring ALK rearrangement, which triggers the development of ALK inhibitors. However, the activation of mesenchymal-epithelial transition factor (c-Met) has emerged as a common cause of acquired resistance induced by sel...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Am J Cancer Res
Main Authors: Wang, Lei, Gao, Mingzhao, Tong, Mengya, Xie, Chengying, He, Ye, Fu, Li, Li, Yun, Fu, Haoyu, Lou, Liguang
Formato: Artigo
Idioma:Inglês
Publicado: e-Century Publishing Corporation 2018
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6129499/
https://ncbi.nlm.nih.gov/pubmed/30210922
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares